Telavancin (Vibativ), a new option for the treatment of gram-positive infections

P and T

Volumn 36, Issue 3, 2011, Pages 127-138

  Plotkin, Polina ^a,b   Patel, Khusbu ^b   Uminski, Amy ^b   Marzella, Nino ^b,c  

^a Patient Aligned Care Team ^*  (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; LINEZOLID; METRONIDAZOLE; MIDAZOLAM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; DYSPNEA; FETUS DISEASE; FLUSHING; GRAM POSITIVE INFECTION; HEART REPOLARIZATION; HOSPITAL INFECTION; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; PNEUMONIA; PREGNANCY; PRURITUS; QT PROLONGATION; RECOMMENDED DRUG DOSE; RED MAN SYNDROME; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; TASTE DISORDER; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY DYSFUNCTION; URTICARIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

EID: 79953009090     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Telavancin (Vibativ), prescribing information. San Francisco/Deerfield, Ill.: Theravance/Astellas; September 2009.
2. Vancomycin (Vancocin), prescribing information. Exton, Pa.: ViroPharma; October 2005.
3. Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49(1):195-201. (Pubitemid 40065793)
4. Wong SL, Barriere SL, Kitt MM. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 2008;62:780-783.
5. Sun HK, Duchin K, Nightingale CH. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006; 50(2):788-790. (Pubitemid 43191003)
6. Lodise TP. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2008;52(7):2300-2304.
7. Gotfried MH, Shaw JP, Benton BM, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother 2008;52(1):92-97.
8. Hedge SS, Reyes N, Wiens T. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004;48(8):3043-3050. (Pubitemid 38989173)
9. Wong SL, Sorgel F, Kinzig SF, et al. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/ tazobactam in healthy participants. J Clin Pharmacol 2009;49(7): 816-823.
10. Macgowan AP, Noel AR, Tomaselli S, et al. The pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother, November 15, 2010.
11. Stryjewski M, O'Riordan W, Lau W, et al. Telavancin versus standard therapy of treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40:1601-1607. (Pubitemid 40720810)
12. Stryjewski M, Chu V, O'Riordan W, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50(3):862-867. (Pubitemid 43327787)
13. Stryjewski M, Graham D, Wilson S, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by grampositive organisms. Clin Infect Dis 2008;46:1683-1693. (Pubitemid 351706765)
14. Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: The ATTAIN studies (Abstract 075). Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, April 19-22, 2008. Clin Microbiol Infect 2008;14(Suppl 7):S14.
15. Wong SL, Goldberg MR, Ballow CH. Effect of telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: A randomized, doubleblind, crossover study in healthy subjects. Pharmacotherapy 2010;30(2):136-143.
16. Barriere S, Genter F, Spencer E, et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004;44:689-695. (Pubitemid 38765930)
17. Goldberg MR, Wong SL, Shaw JP, et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy 2010;30(1):35-42.
18. Goldberg MR, Wong SL, Shaw JP, et al. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy 2010;30(8):806-811.
19. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: A comparative review of dalbavancin, oritavancin, and telavancin. Drugs 2010;70(7):859-886.